Answers are grounded in this paper and cite their sources.
Tests AdoXLong semaglutide formulation for effective once-monthly doses in animals, suggesting clinical potential.
Introduction and Objective: AdoXLong technology is designed to deliver sustained peptide circulation for at least one month. This new long-acting peptide platform is based on a biocompatible polymer chemically linked to peptides of interest while maintaining their mechanism of action. AdoXLong was applied to semaglutide to develop a once-a-month formulation. Methods: The bioactivity of AdoXLong Sema was determined in vitro by measuring cAMP production in GLP1-R overexpressing cells. Formulation was tested in rats following a subcutaneous injection. Plasma samples were analyzed by ELISA. Results: In vitro, AdoXLong Sema demonstrates a high affinity to albumin. The intrinsic in vitro potency of GLP1-RA from AdoXLong Sema is well preserved and even slightly increased compared to semaglutide (Relative potency: 151%). A strong decrease of AdoXLong Sema in vitro potency is observed in the presence of human albumin, confirming its high affinity to albumin. Pharmacokinetic analysis of AdoXLong Sema after subcutaneous injection in rats shows an apparent half-life of 24h, i.e. 3.5 times that of semaglutide (Fig. 1). Conclusion: These results indicate that AdoXLong Sema offers an effective strategy to extend the half-life and duration of action of semaglutide, potentially enabling once-monthly administration in humans. Disclosure A. Marechal: Employee; Current; ADOCIA. M. Gaudier: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. O. Soula: Board Member; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. Employee; Current; ADOCIA. C. Mégret: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. S. Hakim: Employee; Current; ADOCIA. Y. Chan: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. A. Gaffuri: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. B. Plancq: None. A. Martin: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. K. Lelu: Employee; Current; ADOCIA. J. Dutreuil: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. E. Dauty: Employee; Current; ADOCIA. U. Naessens: Employee; Current; ADOCIA.
No takes yet. Share an insight, caveat, or question.
MARECHAL et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: